• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

EuroPCR Roundup: Bioresorbable stents show promise, but metallic drug-eluting stents remain standard

May 22, 2017 By Sarah Faulkner

EuroPCR logoMicell Technologies‘ sirolimus-eluting absorbable polymer coronary stent met the primary endpoint in the Dessolve III clinical trial, according to 12-month data published at EuroPCR. The stent demonstrated non-inferior safety and effectiveness outcomes compared to Xience‘s everolimus-eluting coronary stent system.

The 1,400-patient study evaluated the MiStent in patients with symptomatic coronary artery disease, including chronic stable angina, silent ischemia and acute coronary syndrome. All study participants qualified for percutaneous coronary interventions.

“MiStent met the primary non-inferiority endpoint of target lesion failure at 12 months, with numerically lower TLF and target lesion revascularization rates. TLR rates for MiStent were numerically lower at all time points following the procedure, and by 1 year that difference grew to 1.2%. These results speak to the potential value of slower, controlled drug release allowing for sustained drug presence,” Dr. Robbert de Winter, from the Academic Medical Center in Amsterdam, said in prepared remarks. “These trial results, in conjunction with the 5-year results from the Dessolve I and II studies, provide further evidence of the potential value of this technology relative to current DES performance expectations from the perspectives of both safety and efficacy.”

MiStent has CE Mark approval in the European Union, but is not approved in the U.S.

“These results appear to validate the unique premise of Micell’s supercritical fluid technology platform, which allows drug in micro-crystalline form to be combined with a fast-dissolving polymer and applied as a coating on an ultra-thin-strut cobalt chromium stent,” Micell chief medical advisor Dr. Dennis Donohoe added. “These unique features have the potential to offer meaningful clinical and economic benefits to patients and the healthcare system.”

NEXT: Svelte Medical System touts 5-year follow-up of 1st drug-eluting stent-on-a-wire

Pages: Page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8

Filed Under: Cardiovascular, Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals, Vascular Tagged With: Abbott Laboratories, amaranthmedical, Medtronic, Micell Technologies, Reva Medical, sveltemedicalsystem, xience

IN CASE YOU MISSED IT

  • Omnipod 5 rollout for type 2 rolls on as Insulet pursues next-gen automation
  • LifePlus reports clinical validation of non-invasive glucose, blood pressure monitor
  • Abbott Diabetes head talks Medtronic partnership, exciting times ahead
  • PharmaSens, SiBionics innovatively combine tech in all-in-one insulin patch pump
  • Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS